Find research datasets worth reusing
Search datasets from major research repositories and use ShareScore to quickly assess how well each record supports discovery, access, and reuse.
1,012
datasets available to search
ShareScore release 0.9.0
Dataset results
1,012 results for “neurological”
High-Throughput Drug Discovery for a Rare Neurological Disorder: Uncovering a Novel Therapeutic Opportunity for the 19q12 Autism Spectrum Disorder [19q12 neurons baseline data]
GEO Series GSE292758. Homo sapiens. 5 samples. Type: Expression profiling by high throughput sequencing.
Loss of Neurological Disease HSAN-I-Associated Gene SPTLC2 Impairs CD8+ T Cell Responses to Infection by Inhibiting T Cell Metabolic Fitness
GEO Series GSE112715. Mus musculus. 12 samples. Type: Expression profiling by high throughput sequencing.
Comprehensive Analysis of TCR-β Repertoire in Patients with Neurological Immune-mediated Disorders
GEO Series GSE121082. Homo sapiens. 106 samples. Type: Other.
TEFM variants impair mitochondrial transcription elongation causing childhood-onset neurological disease
GEO Series GSE185245. Homo sapiens. 35 samples. Type: Expression profiling by high throughput sequencing.
Hippocampal and neocortex transcriptome sequencing data from 17 mesial temporal lobe epilepsy patients and 2 neocortex samples from neurologically healthy controls
GEO Series GSE134697. Homo sapiens. 36 samples. Type: Expression profiling by high throughput sequencing.
Multi-tissue DNA methylation analysis to identify an appropriate surrogate tissue for a unique neurological tissue specific to spina bifida
GEO Series GSE313496. Homo sapiens. 81 samples. Type: Methylation profiling by genome tiling array.
Figure 2 from: Drenska M, Elitova S, Grigorova V, Naseva E, Getov I (2019) Analysis of primary outpatient data for off-label use of medicines in neurology. Pharmacia 66(4): 165-170. https://doi.org/10.3897/pharmacia.66.e36620
Figure 2 Type of off-label use.
Figure 1 from: Drenska M, Elitova S, Grigorova V, Naseva E, Getov I (2019) Analysis of primary outpatient data for off-label use of medicines in neurology. Pharmacia 66(4): 165-170. https://doi.org/10.3897/pharmacia.66.e36620
Figure 1 Off-label use with regard to patients and prescriptions.
Neurologic morbidity and functional independence in adult survivors of childhood cancer
<p>SAS data set "<span><a href="../api/records/10878104/draft/files/neuro_morbi_indep.sas7bdat/content" target="_blank" rel="noopener noreferrer">neuro_morbi_indep.sas7bdat</a></span>" contains data for publication "Neurologic morbidity and functional independence in adult survivors of childhood cancer". Variables and formats are in the file "<span><a href="../api/records/10878104/draft/files/Variables%20and%20formats%20for%20neuro_morbi_indep.docx/content" target="_blank" rel="noopener noreferrer">Variables and formats for neuro_morbi_indep.docx</a></span>".</p>
Data from: Education research: simulation training for neurology residents on acquiring tPA consent: an educational initiative
[No abstract entered]
Clinical course of neurologic adverse events associated with immune checkpoint inhibitors
<p>In the present dataset we collected clinical, demographic and outcome data of a large cohort of patients with neurological immune-related adverse events associated with immune check-point inhibitors. </p>
BIOMARKERS OF ATHEROGENESIS AND CLINICAL NEUROLOGICAL CHARACTERISTICS OF THE INTERNAL CAROTY ARTERY
<p><em><span>Atherosclerosis is a multifactorial and widespread process that underlies the development of cardiovascular and cerebrovascular diseases. Atherosclerotic damage of cerebral vessels is a long-term process that passes through several stages during its development, in particular, the "asymptomatic" stage. Considering that atherosclerotic damage of carotid arteries is widely important in the development of acute cerebrovascular disorders, atherosclerotic damage of internal carotid arteries in patients with asymptomatic stenosis was generally considered as a model of atherosclerosis in brachiocephalic arteries (BSA). In this article, clinical-neurological and dopplerographic indicators of the development of the atherosclerotic process in patients with asymptomatic stenosis of the carotid artery are evaluated.</span></em></p>
Data from: A new way to estimate neurologic disease prevalence in the United States
Objective: Considerable gaps exist in knowledge regarding the prevalence of neurologic diseases, such as multiple sclerosis (MS), in the United States. Therefore, the MS Prevalence Working Group sought to review and evaluate alternative methods for obtaining a scientifically valid estimate of national MS prevalence in the current health care era. Methods: We carried out a strengths, weaknesses, opportunities, and threats (SWOT) analysis for 3 approaches to estimate MS prevalence: population-based MS registries, national probability health surveys, and analysis of administrative health claims databases. We reviewed MS prevalence studies conducted in the United States and critically examined possible methods for estimating national MS prevalence. Results: We developed a new 4-step approach for estimating MS prevalence in the United States. First, identify administrative health claim databases covering publicly and privately insured populations in the United States. Second, develop and validate a highly accurate MS case-finding algorithm that can be standardly applied in all databases. Third, apply a case definition algorithm to estimate MS prevalence in each population. Fourth, combine MS prevalence estimates into a single estimate of US prevalence, weighted according to the number of insured persons in each health insurance segment. Conclusions: By addressing methodologic challenges and proposing a new approach for measuring the prevalence of MS in the United States, we hope that our work will benefit scientists who study neurologic and other chronic conditions for which national prevalence estimates do not exist.
Effect of neurological screening on early dementia detection in southern Italy
<p>Objective</p> <p>Population screening can facilitate early diagnosis of dementia and improve disease management. This study examined the effects of a screening campaign for neurodegenerative disorders on the early diagnosis of dementia using 2-year follow-up data.</p> <p>Methods</p> <p>A 5-day screening campaign was conducted that comprised neurological, neuropsychological and other specialist examinations. Identification of alterations during the neurological examination was followed-up by further diagnostic examinations to confirm the neurological impairment.</p> <p>Results</p> <p>Neurological alterations were observed in 39% of the screened subjects, who were mostly diagnosed with mild cognitive impairment and referred to a dementia and cognitive disorders centre. Suspicion of neurological impairment was a risk factor for inclusion in a specific neurological ambulatory follow-up and a condition for exemption from payment for medical examinations.</p> <p>Conclusions</p> <p>Neurodegenerative screening initiatives should include subjects selected by general practitioners. It would be useful to create a network including primary care physicians and cognitive disorder centres. Telemedicine tools (e.g., teleconsulting) could also be used to facilitate early diagnosis.</p>
One comprehensive clinical neurologic examination is sufficient to declare brain death
<p>Objective: To fill the evidence gap on the value of a single (SBD) or dual brain death (DBD) exam by providing data on irreversibility of brain function, organ donation consent and transplantation </p> <p>Methods: 12-year tertiary hospital and organ procurement organization data on brain death (BD) were combined and outcomes, including consent rate for organ donation and organs recovered and transplanted after SBD and DBD were compared after multiple adjustments for co-variates </p> <p>Results: two-hundred sixty-six patients were declared BD, 122 after SBD and 144 after DBD. Time from event to BD declaration was longer by an average of 20.9 hours after DBD (p=0.003). Seventy-five (73%) families of patients with SBD and 86 (72%) with DBD consented for organ donation (p=0.79). The number of BD exams was not a predictor for consent. No patient regained brain function during the periods following BD. Patients with SBD were more likely to have at least one lung transplanted (p = 0.033). The number of organs transplanted was associated with the number of exams [beta coefficient, (95% CI) -0.5 (-0.97 to -0.02), p=0.044], along with age (for 5 year increase, -0.36 (-0.43 to -0.29), p<0.001) and PaO2 level (for 10 mmHg increase, 0.026 (0.008 to 0.044), p=0.005) and decreased as the elapsed time to BD declaration increased (p=0.019). </p> <p>Conclusions: A single neurologic examination to determine brain death is sufficient in patients with non-anoxic catastrophic brain injuries. A second examination is without additional yield in this group and its delay reduces the number of organs transplanted. </p>
Retrospective Evaluation of Perampanel in a French Neurology and Epileptology Department (Hospices Civil de Lyon)
ClinicalTrials.gov study NCT02876289. IPD Sharing: NO. Countries: 1. Publications: 0.
Cerebral Oximetry and Neurological Outcomes in Aortic Arch Surgery Patients
ClinicalTrials.gov study NCT01149148. IPD Sharing: Not stated. Countries: 0. Publications: 0.
Creation of a Normal Database for FluoroDeoxyGlucose-Positron Emission Tomography (FDG-PET) Neurological Examinations
ClinicalTrials.gov study NCT02858167. IPD Sharing: NO. Countries: 1. Publications: 0.
Correlation of Motor Metrics and Neurological Data
ClinicalTrials.gov study NCT05462080. IPD Sharing: UNDECIDED. Countries: 1. Publications: 0.
Kundalini Yoga & Healthy Neurological Aging
ClinicalTrials.gov study NCT04726072. IPD Sharing: NO. Countries: 1. Publications: 0.
ScienceDex guides
Understand access before you commit
These curated guides explain access requirements, typical timelines, costs, and reuse considerations for widely used research datasets.
Allen Brain Atlas
Allen Brain Atlas is an Allen Institute collection of brain map atlases, datasets, APIs, and analysis tools covering mouse, human, and non-human primate brain resources.
Annotated Behaviour and Observability Dataset (ABODe)
ABODe is a University of Edinburgh DataShare dataset for behavior classification in group-housed mice using home-cage video, identities, bounding boxes, ground-plate positions, and annotator labels.
DANDI Archive for NWB datasets
DANDI is a BRAIN Initiative archive for publishing and sharing neurophysiology data, including electrophysiology, optophysiology, and behavioral data packaged as NWB and related standards.
International Brain Laboratory public data
The International Brain Laboratory public data releases expose standardized mouse decision-making experiments, including Neuropixels recordings, widefield calcium imaging, behavior, and session metadata accessed through the ONE API.
OpenNeuro
OpenNeuro is a free, open platform for sharing neuroimaging datasets, with public search, dataset pages, and download paths for web, S3, DataLad, and the OpenNeuro CLI.